Literature DB >> 8834580

Clinical determinants of treatment failure in patients with pseudomyxoma peritonei.

P H Sugarbaker1, V Fernández-Trigo, F Shamsa.   

Abstract

Pseudomyxoma peritonei is a mucinous cancer of low biologic aggressiveness that disseminates widely throughout the abdominopelvic cavity prior to diagnosis. Complete control of the disease process on peritoneal surfaces should translate into long-term disease-free survival. In a series of 120 patients with pseudomyxoma peritonei, 46 were defined as treatment failures after cytoreductive surgery and regional chemotherapy. Clinical features that correlated significantly with treatment failure were tumor site (colon vs. appendix), histopathology grade (grade II vs. grade I), preoperative cancer volume, and completeness of cancer removal by cytoreductive surgery. For grade I histopathology, treatment failure was 10 times more common after incomplete versus complete cytoreduction. For grade II histopathology treatment failure was three times more common with incomplete cytoreduction. Death from other causes was more common over the age of 65, and stroke was the most common diagnosis. The major causes of morbidity and mortality were related to progressive disease in the abdomen causing intestinal obstruction and biliary obstruction. When treatment failures were categorized as surgical (failure to cytoreduce) versus medical (failure of chemotherapy to sustain a response), there were 27 surgical and 10 medical treatment failures. Improvements in the cytoreductive approach await the development of surgical technologies to increase the total clearance of cancer from the abdominal cavity and chemotherapy treatments that are complete enough to sustain control of small-volume residual disease on all peritoneal surfaces.

Entities:  

Mesh:

Year:  1996        PMID: 8834580     DOI: 10.1007/978-1-4613-1245-1_11

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  5 in total

1.  Pseudomyxoma peritonei: disseminated peritoneal adenomucinosis variant.

Authors:  Anshuman Pandey; Ashish Kumar Mishra
Journal:  BMJ Case Rep       Date:  2011-05-03

2.  Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.

Authors:  Jerome T O'Connell; James S Tomlinson; Alice A Roberts; Kathryn F McGonigle; Sanford H Barsky
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

3.  Pseudomyxoma peritonei--a revisit: report of 2 cases and literature review.

Authors:  Chunyanca Li; Rani Kanthan; S C Kanthan
Journal:  World J Surg Oncol       Date:  2006-09-01       Impact factor: 2.754

4.  The role of mucin cell-free DNA detection as a new marker for the study of acellular pseudomyxoma peritonei of appendicular origin by liquid biopsy.

Authors:  Damián García-Olmo; Susana Olmedillas-López; Delia Cortés-Guiral; Pedro Villarejo; Irene López Rojo; Héctor Guadalajara; Soledad García Gómez-Heras; Mariano García-Arranz
Journal:  Ther Adv Med Oncol       Date:  2020-06-24       Impact factor: 8.168

5.  Pseudomyxoma peritonei.

Authors:  Maria Homeag; Viorela Enachescu; Luci Elena Pavel; B Zaharia; N Manescu
Journal:  Curr Health Sci J       Date:  2009-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.